Last updated: June 25, 2026
Cosmo Technologies Limited v. Alvogen Pine Brook LLC (1:15-cv-00193): Litigation Summary, Patent Issues, and Practical Risk Assessment
Executive summary
The case Cosmo Technologies Limited v. Alvogen Pine Brook LLC, 1:15-cv-00193 is a US Hatch-Waxman patent dispute in which Cosmo asserted patent rights against a generic or generic-substitute product targeting a Cosmo-branded prescription drug. The dispute is procedurally consistent with an ANDA Paragraph IV framework: Cosmo’s pleadings would have identified asserted Orange Book patents, and Alvogen would have challenged validity and/or infringement, typically paired with a regulatory launch timeline controlled by FDA review and any final settlement or court injunction.
Because the record-specific elements needed for a complete, accurate litigation dossier (asserted patent numbers, claims at issue, district court holdings, dates of key events, PTAB activity if any, and settlement/injunction status) are not provided in the prompt, a complete litigation summary cannot be produced without introducing errors.
What is the docket context for 1:15-cv-00193 and what type of case is it?
Answer (high level): 1:15-cv-00193 is a federal patent infringement action tied to an ANDA-related Paragraph IV licensing dispute pattern, with injunctive relief and infringement/invalidity determinations as the core adjudicatory items.
What court and jurisdiction governs the dispute?
- Federal district court: United States District Court
- Case number: 1:15-cv-00193
- Parties: Cosmo Technologies Limited (plaintiff) vs Alvogen Pine Brook LLC (defendant)
Why does docket number matter for freedom-to-operate?
The case posture, including whether it resulted in:
- a final merits decision on infringement/invalidity,
- a dismissal (with or without prejudice),
- a consent injunction,
- a covenant not to sue,
- or a settlement leading to forfeiture, license, or date-certain carveouts,
is what drives downstream generic entry risk for the relevant ANDA.
Which patents were asserted in Cosmo v. Alvogen Pine Brook?
Answer: Not determinable from the information provided.
How to identify the asserted patents (what matters to litigators)
For a Paragraph IV pharma case, the asserted set usually comes from the relevant drug’s FDA Orange Book list at the time of ANDA filing:
- active ingredient and dosage form (oral solid, topical, etc.)
- formulation patents (compositions, polymorphs, particle sizes, stabilizers)
- method-of-use patents (therapeutic regimen claims)
- manufacturing/process patents
- packaging/device patents if applicable
What infringement theories were typically used in these cases?
Answer: Not determinable from the information provided.
Likely claim categories (only as a framework)
In Cosmo vs generic disputes, infringement theories typically split into:
- literal infringement of specific independent claims
- doctrine of equivalents for formulation parameters
- induced or contributory infringement where the ANDA product performs the claimed method
- product-by-process mapping (if process claims exist)
How did Alvogen respond: invalidity, non-infringement, and FDA regulatory timing?
Answer: Not determinable from the information provided.
Standard Paragraph IV defenses
- non-infringement (no claim coverage for the generic formulation or use)
- anticipation/obviousness under 35 USC 102/103
- lack of written description and enablement (35 USC 112)
- indefiniteness (35 USC 112(b))
- patent unenforceability defenses (often inequitable conduct, if pleaded)
Did the court grant injunctions, stay launch, or enter consent orders?
Answer: Not determinable from the information provided.
What outcomes control generic entry risk?
- Preliminary injunction: blocks launch pending merits (rare if not supported by evidence and balance)
- Permanent injunction: blocks launch until patent expiry or redesign
- Settlement: may include a “launch date” commitment, patent license, or market carveout
- Dismissal: may permit entry depending on the dismissal’s basis and scope
What was the procedural timeline for 1:15-cv-00193?
Answer: Not determinable from the information provided.
What dates typically matter to business decisions
- complaint filing date
- service and first appearance dates
- Markman claim construction schedule and decision date (if held)
- summary judgment milestones
- trial dates (if reached)
- any appeal to the Federal Circuit
- any FDA acceptance/approval dates for the ANDA (often the launch control point)
How does this litigation affect freedom-to-operate for Cosmo’s branded product?
Answer: Not determinable from the information provided.
What you need from the merits to assess FTO
A correct FTO conclusion requires:
- which patents were adjudicated
- the scope of infringement findings (which claims were held infringed)
- the scope of validity findings (invalidated claims vs preserved claims)
- whether any final injunction was issued and for what product form
- whether the defendant designed around, licensed, or settled
How strong is Cosmo’s patent estate as reflected by this case?
Answer: Not determinable from the information provided.
Indicators patent teams use
- number of asserted patents per family
- claim survivability post-motion practice
- whether Cosmo succeeded on claim construction
- whether invalidity grounds were rejected
- whether multiple families were involved (composition and use)
Did the case involve claim construction or amended pleadings that narrowed issues?
Answer: Not determinable from the information provided.
Why claim construction drives outcomes
In formulation and method-of-use cases, claim terms like:
- particle size distributions,
- polymorph or crystalline form,
- dissolution rate thresholds,
- temperature or humidity stability parameters,
- “effective amount” language,
often become dispositive. Without the court’s constructions, analysis would be speculative.
Was there a settlement or license agreement, and what were the commercial terms?
Answer: Not determinable from the information provided.
Common settlement term patterns in ANDA litigations
- agreed launch date aligned to dismissal/expiry
- license with running royalties or one-time payments
- covenant not to sue for certain patents after a certain event
- design-around permission with carveouts
What is the regulatory pathway link: ANDA timing and Orange Book status?
Answer: Not determinable from the information provided.
Why Orange Book listings must match the asserted patents
Orange Book listings create a patent-by-patent map from:
- NDA holder’s listed patents
- defendant’s notice and Paragraph IV certifications
- complaint allegations tied to specific patents and claims
Without the Orange Book patent list and the specific asserted patents in the pleadings, a compliant mapping cannot be built.
Key Takeaways
- The docket 1:15-cv-00193 is consistent with a Hatch-Waxman patent dispute structure, but a litigation summary with actionable details (asserted patents, claim outcomes, key rulings, injunction/settlement status, and practical launch impact) cannot be produced from the information supplied.
- A correct analysis requires record-specific facts: asserted patent numbers, procedural milestones, claim construction outcomes, and final case disposition.
FAQs
1) What patents did Cosmo assert in 1:15-cv-00193?
Not determinable from the provided information.
2) What was Alvogen’s Paragraph IV certification basis in this case?
Not determinable from the provided information.
3) Did the court construe any claim terms in Cosmo v. Alvogen Pine Brook?
Not determinable from the provided information.
4) Did the case result in a settlement, license, or consent judgment affecting launch dates?
Not determinable from the provided information.
5) What is the Orange Book status impact of this specific litigation for the relevant Cosmo product?
Not determinable from the provided information.
References
No sources were provided in the prompt, and no case record details were included to support accurate citation.
